Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group.
Calais da Silva, Fernando
Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. [electronic resource] - European urology Aug 2014 - 232-9 p. digital
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1873-7560
10.1016/j.eururo.2013.03.055 doi
Adenocarcinoma--blood
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Cyproterone Acetate--administration & dosage
Disease Progression
Europe
Humans
Male
Middle Aged
Prostate-Specific Antigen--blood
Prostatic Neoplasms--blood
Quality of Life
Sexuality
Survival Rate
Time Factors
Triptorelin Pamoate--administration & dosage
Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. [electronic resource] - European urology Aug 2014 - 232-9 p. digital
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1873-7560
10.1016/j.eururo.2013.03.055 doi
Adenocarcinoma--blood
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Cyproterone Acetate--administration & dosage
Disease Progression
Europe
Humans
Male
Middle Aged
Prostate-Specific Antigen--blood
Prostatic Neoplasms--blood
Quality of Life
Sexuality
Survival Rate
Time Factors
Triptorelin Pamoate--administration & dosage